Attenuated live vaccine against mycoplasmal pneumonia of swine (MPS) and use thereof

Patent metadata

Field	Value
Publication number	US-9849168-B2
Application number	US-201415113909-A
Country	US
Kind code	B2
Filing date	Jan 26, 2014
Priority date	Jan 26, 2014
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

Disclosed are an attenuated live vaccine against mycoplasmal pneumonia of swine (MPS) and use thereof. In the present invention, pathological lung tissues of swine having typical Mycoplasma hyopneumoniae (Mhp) infection and no obvious other pathogenic infections are screened, and subcultured 100 generations in lungs of newborn rabbits; then, Mhp strains are isolated and serially subcultured in a medium; and the Mhp strain AN306 is obtained by screening a plurality of strains, which is deposited with an accession number: CCTCC NO. M2012431. Also disclosed is a live vaccine formulation against MPS prepared on the basis of the attenuated strain and comprising live attenuated strain, a pharmaceutically acceptable carrier or excipient, and optionally an adjuvant and immunogens of other pathogens.

First claim

What is claimed is:

1. An attenuated Mycoplasma hyopneumoniae (Mhp) strain AN306, which is deposited in China Center for Type Culture Collection (CCTCC) with an accession number: CCTCC NO. M2012431.

2. A method comprising:
administering an effective amount of the attenuated Mhp strain AN306 according to claim 1 to a pig in order to treat an Mhp infection.

3. An immunogenic composition against mycoplasmal pneumonia of swine (MPS), comprising the attenuated Mhp strain AN306 according to claim 1 .

4. The immunogenic composition against MPS according to claim 3 , further comprising a pharmaceutically acceptable carrier or excipient.

5. The immunogenic composition against MPS according to claim 3 , further comprising an immunization adjuvant.

6. The immunogenic composition against MPS according to claim 3 , further comprising an immunogen of an additional pathogen.

7. The immunogenic composition against MPS according to claim 6 , wherein the additional pathogen includes at least one of viruses, bacteria, fungi, and parasites.

8. The immunogenic composition against MPS according to claim 7 , wherein the additional pathogen is porcine circovirus, Haemophilus parasuis , porcine reproductive and respiratory syndrome virus, Mycoplasma hyorhinis, Mycoplasma hyosynoviae , or swine influenza virus.

9. The immunogenic composition against MPS according to claim 3 , wherein the vaccine is in the form of an intrapulmonary injectable formulation, an intramuscular injectable formulation, an aerosol, an oral formulation, or a nasal drop.

10. A method for preparing the immunogenic composition against MPS according to claim 3 , comprising combining an effective amount of the Mhp strain AN306 with a pharmaceutically acceptable carrier or excipient, an immunization adjuvant, and an immunogen of an additional pathogen.

11. The method according to claim 2 , wherein the effective amount of the attenuated Mhp strain AN306 is administered in the form of an intrapulmonary injectable formulation, an intramuscular injectable formulation, an aerosol, an oral formulation, or a nasal drop.

Assignees

• Jiangsu Acad Agricultural Sci

Inventors

• Shao Guoqinq
• Xiong Qiyan
• Liu Maojun
• Feng Zhixin
• Wei Yanna
• Wang Haiyan
• Bai Fangfang
• Gan Yuan
• Wang Li
• Zhang Daohua
• Liu Dongxia
• Hua Lizhong
• Wu Yuzi
• Bai Yun
• Wang Zhanwei

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61K2039/522

  avirulent or attenuated · CPC title

• A61K39/0241 Primary

  Mollicutes, e.g. Mycoplasma, Erysipelothrix · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title